DBT invites comments on draft guidelines for evaluation of nanopharmaceuticals

The Department of Biotechnology (DBT) has invited comments on “Guidelines for evaluation of nanopharmaceuticals in India” from the institutions, industry and researchers upto 10th March

0
226

New Delhi: The Department of Biotechnology (DBT) has invited comments on “Guidelines for evaluation of nanopharmaceuticals in India” from the institutions, industry and researchers engaged in research and development in nanobiotechnology. The comments or observations pertaining to the same may be conveyed positively by 10th March, 2019 to nanobiotech.dbt@nic.in.

Since 2007, the DBT initiated funding R&D in the area of nanobiotechnology as the top biotech policy organization has given special emphasis on applications in various sectors of life sciences. It is also mandated to bring out manuals or guidelines specifying procedures that will help in regulatory process pertaining to development and commercialization of nano products in bio-sectors in India.

From time to time, various scientists and stakeholders have felt the need to have specific guidelines for evaluation of products in various sector of biological sciences developed through interventions of nanotechnology.

Accordingly the department (through Indian Society of Nanomedicine) has formulated the draft “Guidelines for evaluation of nanopharmaceuticals in India” after series of consultations with the stakeholders. The department had organized an inter-ministerial meeting recently and the draft guidelines have been further revised.

Click here to download Proposed Guidelines

Those who want to submit their comments have to mention “Comments on Nano Guidelines” in the subject line. They have to also mention full name, affiliation and correspondence address at the email signature.